| Literature DB >> 24885015 |
Quang Van Vu1, Taizo Wada, Huong Thi Minh Le, Hai Thanh Le, Anh Thi Van Nguyen, Ohara Osamu, Akihiro Yachie, Sang Ngoc Nguyen.
Abstract
BACKGROUND: X-linked agammaglobulinemia (XLA) is a primary immune deficiency characterized by recurrent bacterial infections and profoundly depressed serum immunoglobulin levels and circulating mature B cells. It is caused by mutations of the Bruton tyrosine kinase (BTK) gene and is the most common form of inherited antibody deficiency. To our knowledge, this is the first report of XLA from Vietnam.Entities:
Mesh:
Substances:
Year: 2014 PMID: 24885015 PMCID: PMC4054903 DOI: 10.1186/1471-2431-14-129
Source DB: PubMed Journal: BMC Pediatr ISSN: 1471-2431 Impact factor: 2.125
Clinical pictures of 4 XLA patients
| Age at onset (y) | 6 | 1 | 0.8 | 2 |
| Age at diagnosis* (y) | 10 | 6 | 11 | 5 |
| Present age (y) | 13 | 8 | 15 | Died at 8 Y |
| Family history | + | + | - | - |
| First symptom | Septicemia | Otitis media | Otitis media | Otitis media |
| Otitis media | + | + | + | + |
| Sinusitis | + | - | + | - |
| Pneumonia | + | + | + | + |
| Bronchiectasis | + | - | + | - |
| Arthritis | + | - | - | + |
| Skin infection | + | + | - | - |
| Septicemia | + | + | + | + |
| Meningitis/encephalitis | + | - | + | - |
| Recurrent diarrhea | - | - | - | + |
| Tonsils | Absent | Hypoplastic | Absent | Hypoplastic |
| Duration of IVIG treatment (m) | 25 | 17 | 33 | 12 |
y, years; m, months; IVIG, intravenous immune globulin; +, yes; -, no.
*Age of confirmed agammaglobulinemia.
Immunological features of 4 XLA patients
| WBC (×109/L) | 15.1 | 9.4 | 8.8 | 4.6 | 5-10 | |
| Neutrophils (×109/L) | 11.2 | 5.1 | 4.3 | 2.1 | 1.5-5 | |
| Lymphocytes (×109/L) | 3.7 | 4,2 | 4.4 | 2.4 | 1.5-5 | |
| Ig (g/l) | IgG | 0.06 | 2.18 | 1.7 | 0.01 | 6-15 |
| IgA | < 0.01 | 0.03 | 0.02 | 0.01 | 1.5-2.25 | |
| IgM | < 0.01 | 0.21 | 0.06 | 0.13 | 0.75-1.5 | |
| CD19+ (%) (/μL) | < 0.1 | < 0.1 | < 0.1 | 1.9 (58) | 6-25 | |
| CD3+ (%) (/μL) | 95 (3535) | 93 (3564) | 89 (3982) | 95 (2335) | 55-84 | |
| CD4+ (%) (/μL) | 29 (1078) | 45 (1707) | 36 (1616) | 15 (367) | 31-60 | |
| CD8+ (%) (/μL) | 59 (2209) | 37 (1404) | 47 (2102) | 73 (1792) | 13-41 | |
| CD4+/CD8+ | 0.49 | 1.22 | 0.77 | 0.2 | 0.9-3.1 | |
WBC, white blood cells; Ig, immunoglobulin.
BTK mutation analysis in 4 XLA patients
| 1 | Exon 18 | c.1770delG | SH1 | p.Gly594fsX54 | N.D. |
| 2 | Exon 14 | c.1249A > T* | SH2 | p.Lys417X | N.D. |
| Exon 18 | c.1899C > T** | SH1 | |||
| 3 | Exon 17 | c.1742delG* | SH1 | p.Ala582LeufsX4 | Carrier |
| 4 | Exon 6 | c.441G > A | TH | p.Trp147X | N.D. |
*Novel mutation; **silent polymorphism; N.D., not done; SH1, catalytic kinase domains; SH2, Src homology 2 domain; TH, Tec homology domain.